Overview

* Pacira Q2 2025 revenue of $181.1 mln missed analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 beats consensus, indicating strong operational performance

* Company repurchased 2 mln shares, costing $50 mln, showing confidence in strategy

Outlook

* Pacira narrows 2025 revenue guidance to $730 mln-$750 mln

* Company raises 2025 non-GAAP gross margin forecast to 78-80%

* Pacira reiterates 2025 non-GAAP R&D expense at $90 mln-$105 mln

* Company sees 2025 non-GAAP SG&A expense at $290 mln-$320 mln

Result Drivers

* ZILRETTA EXPANSION - Strategic collaboration with Johnson & Johnson MedTech to expand ZILRETTA's market reach

* MANUFACTURING EFFICIENCIES - Large-scale EXPAREL manufacturing process improves gross margins and inventory management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $181.10 $183 mln

Revenue mln (6

Analysts

)

Q2 Beat $0.74 $0.71 (6

Adjusted Analysts

EPS )

Q2 Beat $36 mln $34.70

Adjusted mln (6

Net Analysts

Income )

Q2 Net -$4.80

Income mln

Q2 Beat $54.30 $51.70

Adjusted mln mln (5

EBITDA Analysts

)

Q2 Cash $445.90

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Pacira Biosciences Inc ( PCRX ) is $30.00, about 23.5% above its August 4 closing price of $22.94

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)